The Value of Sangamo, Merck and AstraZeneca News

Sangamo Biosciences: Is it a Comeback?
Genome editing allows the creation of therapeutics that can modify the genome in a living cell, providing unprecedented reach that would help the creation of treatments for genetic diseases. The dream about emerging solutions through genome editing techniques, which could correct genetic mutations causing diseases seems to be turning into reality. Among the innovative firms in this field, Sangamo Therapeutics (SGMO) uses its proprietary technology zinc finger DNA-binding proteins (ZFPs), which is capable of recognizing and binding to DNA sequences. Sangamo’s researchers engineer these . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.